Dexrazoxane inhibits the growth of esophageal squamous cell carcinoma by attenuating SDCBP/MDA-9/syntenin-mediated EGFR-PI3K-Akt pathway activation

Dexrazoxane inhibits the growth of esophageal squamous cell carcinoma by attenuating SDCBP/MDA-9/syntenin-mediated EGFR-PI3K-Akt pathway activation

Abstract Syndecan-binding protein (SDCBP) was reported to stimulate the advancement of esophageal squamous cell carcinoma (ESCC) and could potentially be a target for ESCC treatment. There is a growing corpus of research on the anti-tumor effects of iron chelators; however, very few studies have add...

Descripció completa

Dades bibliogràfiques
Autors principals: Ruijuan Du, Nan Xiao, Li Han, KeLei Guo, Kai Li, Zhiguo Chen, Hui Zhang, Zijun Zhou, Yunlong Huang, Xulin Zhao, Hua Bian
Format: Article
Idioma:English
Publicat: Nature Portfolio 2024-04-01
Col·lecció:Scientific Reports
Matèries:
ESCC
Dexrazoxane
SDCBP/MDA-9/syntenin
EGFR
Cancer treatment
Accés en línia:https://doi.org/10.1038/s41598-024-59665-5

Internet

https://doi.org/10.1038/s41598-024-59665-5

Ítems similars